Dyne Therapeutics, Inc. Annual Report - Fiscal Year Ended December 31, 2025: An Investor's Overview

For investors tracking the cutting edge of biotechnology, this summary offers a clear and concise look at Dyne Therapeutics' performance and strategic direction for the fiscal year ended December 31, 2025.

Business Overview: Pioneering Treatments for Muscle Diseases

Dyne Therapeutics is a clinical-stage biotechnology company dedicated to advancing innovative therapies for serious muscle diseases. Their core strategy centers on their proprietary FORCE™ platform, which precisely delivers therapeutic payloads to muscle tissue. This approach addresses the underlying genetic causes of debilitating muscle conditions. Dyne's status as a "large accelerated filer" and "well-known seasoned issuer" reflects its significant public market presence, maturity, and adherence to robust reporting standards.

Key Pipeline Progress & Strategic Focus:

This past year saw critical advancements across Dyne's lead programs:

• DYNE-101 for Myotonic Dystrophy Type 1 (DM1): This program targets the DMPK gene to reduce toxic RNA. In 2025, Dyne advanced its Phase 1/2 NURTURE clinical trial, focusing on dose escalation and expansion cohorts. Initial data presented earlier in the year showed promising trends in key biomarkers and functional endpoints. This supports the program's potential to address DM1's multi-systemic nature. Dyne anticipates further data readouts in late 2026, which will be crucial for informing potential registrational studies.
• DYNE-251 for Duchenne Muscular Dystrophy (DMD) amenable to exon 51 skipping: DYNE-251 aims to restore dystrophin protein expression in patients with DMD. The Phase 1/2 DELIVER clinical trial progressed well in 2025, with enrollment continuing across multiple dose cohorts. Early biomarker data indicated successful delivery and target engagement. The company remains on track to provide more comprehensive clinical updates, including functional assessments, in mid-2026. This program represents a significant opportunity in a high-unmet-need pediatric population.

Dyne's strategy centers on accelerating these clinical programs, expanding its FORCE platform to new indications, and exploring strategic collaborations to maximize patient reach and therapeutic impact.

Financial Performance

As a clinical-stage biotech, Dyne's financial performance reflects its significant investment in research and development rather than commercial revenue.

• Revenue: In fiscal year 2025, Dyne reported minimal revenue, primarily from existing collaboration agreements. This aligns with the prior year, as the company remains pre-commercial.
• Net Loss: Dyne reported a substantial net loss, which increased from the prior fiscal year. This reflects intensive R&D expenditures and general administrative costs as it advances its clinical pipeline. The company remains in a net loss position, continuing to invest heavily in its drug development programs.
• Research & Development (R&D) Expenses: R&D remained the largest expense category and increased significantly year-over-year, demonstrating Dyne's commitment to its clinical programs. These investments funded ongoing clinical trials, preclinical research, and manufacturing for its lead candidates.
• General and Administrative (G&A) Expenses: G&A expenses also increased, primarily due to costs associated with being a public company, expanding corporate infrastructure, and supporting intellectual property activities.
• Cash Burn: The company experienced a significant cash burn rate throughout the year, consistent with its development stage and the high costs of clinical trials.

Management's Discussion and Analysis (MD&A) Highlights

Management highlighted the strategic allocation of capital to advance the company's proprietary FORCE™ platform and its lead clinical programs, DYNE-101 and DYNE-251. Increased clinical trial activities, manufacturing scale-up, and preclinical research to expand the pipeline primarily drove the increase in net loss and R&D expenses. General and administrative expenses also rose to support growing operational needs and public company compliance.

Management emphasized the company's strong cash position, which is critical for maintaining its operational runway and executing its development strategy without immediate reliance on external financing. The focus remains on achieving key clinical milestones and demonstrating the therapeutic potential of its FORCE platform. Known trends and uncertainties include the inherent risks of clinical development, the need for future funding, and the competitive landscape. Dyne actively manages these through strategic planning and resource allocation.

Financial Health

Dyne maintained a strong financial position as of December 31, 2025.

• Cash, Cash Equivalents, and Marketable Securities: Dyne reported a robust balance of cash, cash equivalents, and marketable securities. Management projects this capital will fund operations and planned capital expenditures well into 2027, providing a critical financial runway for its ambitious development programs.
• Debt: Dyne reported no significant long-term debt, maintaining a strong balance sheet focused on equity financing and existing cash reserves.
• Liquidity: The company's liquidity primarily derives from its cash, cash equivalents, and marketable securities. Management actively monitors cash burn and capital requirements to ensure sufficient resources for ongoing research and development and operational needs.

Competitive Position

Dyne operates in highly competitive and rapidly evolving therapeutic areas, particularly for myotonic dystrophy type 1 (DM1) and Duchenne muscular dystrophy (DMD). The competitive landscape includes established pharmaceutical companies, other biotechnology firms, and academic institutions developing or having developed therapies for these conditions. Competitors may have greater financial, technical, and human resources, as well as more extensive experience in drug development, regulatory approval, and commercialization.

Dyne's competitive strategy centers on differentiating its proprietary FORCE™ platform, designed for precise delivery of therapeutic payloads directly to muscle tissue. This targeted approach aims to overcome limitations of existing or developing therapies, potentially offering superior efficacy, safety, and patient convenience. The company believes its platform's ability to address the underlying genetic causes of muscle diseases, coupled with its focus on specific, high-unmet-need indications, provides a distinct advantage. Dyne also protects its competitive position through robust intellectual property rights covering its platform and product candidates.

Future Outlook

Dyne's future outlook focuses primarily on the continued advancement of its lead clinical programs, DYNE-101 for DM1 and DYNE-251 for DMD. The company anticipates several key clinical milestones in 2026, including further data readouts from the NURTURE and DELIVER trials. These readouts are expected to provide critical insights into its drug candidates' potential efficacy and safety. These data will inform future development decisions, including potential registrational study designs.

Strategically, Dyne plans to:

• Accelerate clinical pipeline development.
• Expand the FORCE™ platform's application to additional muscle disease indications.
• Explore strategic collaborations and partnerships to maximize therapy reach and impact.
• Continue investing in research capabilities to innovate new therapeutic approaches.

Management reiterated confidence in the current cash runway extending well into 2027, providing the necessary resources to execute its near-term strategic objectives. The company remains committed to its mission of bringing transformative therapies to patients suffering from serious muscle diseases.

Key Risks for Investors to Consider:

Investing in a clinical-stage biotechnology company like Dyne involves inherent risks:

• Clinical Trial Success and Regulatory Approval: The success of Dyne's drug candidates (DYNE-101, DYNE-251, and future programs) is highly uncertain. They must demonstrate safety and efficacy in rigorous clinical trials and ultimately secure approval from regulatory authorities like the FDA. Failure at any stage would severely impact the company's prospects.
• Funding and Cash Burn: Dyne is not yet profitable and relies heavily on existing cash reserves and future financing to fund operations. There is no guarantee that additional funding will be available on favorable terms, or at all, which could force delays or abandonment of programs.
• Competition: The fields of DM1 and DMD are highly competitive, with other companies developing similar or alternative therapies. Dyne's ability to compete effectively depends on the differentiation, efficacy, and safety profile of its drug candidates.
• Intellectual Property Protection: Dyne's success hinges on its ability to obtain, maintain, and enforce patent protection for its FORCE platform and drug candidates. Changes in patent law, challenges from competitors, or the inability to secure broad protection could undermine its competitive advantage.
• Ownership Concentration and Influence: A relatively small group of executive officers, directors, and their affiliates collectively own a significant portion of Dyne's stock. This concentration could allow them to exert substantial influence over major corporate decisions, potentially in ways that do not always align with the interests of all shareholders.
• Management Discretion Over Funds: Management has broad discretion in allocating the company's cash and investments. Ineffective use of these funds could negatively impact financial results and stock value.
• No Dividends Expected: Dyne does not anticipate paying cash dividends in the foreseeable future. It plans to reinvest all earnings back into the business to fuel growth. Investors should expect returns solely through potential stock price appreciation.
• Potential Share Dilution: A large number of shares are eligible for future sale, and the company may issue additional shares to raise capital. Such events could increase the number of outstanding shares, potentially diluting the value of existing shares and putting downward pressure on the stock price.
• Increased Compliance Costs: As a large accelerated filer, Dyne faces higher legal, accounting, and compliance costs due to stricter regulatory requirements (e.g., Sarbanes-Oxley Act). This can impact profitability compared to smaller companies.
• Internal Control Effectiveness: Maintaining effective internal controls over financial reporting is complex and costly. Any failure could lead to inaccurate financial statements, loss of investor confidence, and potential regulatory scrutiny.
• Anti-Takeover Provisions: Dyne has corporate governance provisions, such as a classified board and the ability to issue preferred stock. These could make it more difficult for a third party to acquire the company or for shareholders to effect a change in management. This might limit the potential for a premium acquisition price.

Dyne Therapeutics navigates the complex landscape of drug development. Its future success largely depends on the clinical and regulatory outcomes of its promising pipeline and its ability to manage the inherent risks of a clinical-stage biotechnology company. Investors should carefully weigh these factors when considering an investment in Dyne.